Astrazeneca (AZN) Non-Current Deferred Tax Liability (2009 - 2026)

Astrazeneca (AZN) has reported Non-Current Deferred Tax Liability for 18 consecutive years, with -$3.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability rose 2.31% year-over-year to -$3.5 billion; the TTM figure through Mar 2026 stood at -$3.5 billion (up 2.31% YoY), while the FY2025 annual figure was -$3.5 billion, down 205.9% from the prior year.
• Non-Current Deferred Tax Liability came in at -$3.5 billion for Q1 2026 at Astrazeneca, up from -$3.5 billion in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $3.3 billion in Q4 2024, with the low at -$5.6 billion in Q1 2022.
• Average Non-Current Deferred Tax Liability over 5 years is -$2.4 billion, with a median of -$3.5 billion recorded in 2026.
• Across the five-year window, Non-Current Deferred Tax Liability surged 50.32% in 2023 and slumped 205.9% in 2025, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $2.9 billion in 2022, then slipped by 3.4% to $2.8 billion in 2023, then increased by 16.21% to $3.3 billion in 2024, then plunged by 205.9% to -$3.5 billion in 2025, then grew by 0.83% to -$3.5 billion in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered -$3.5 billion, -$3.5 billion, and -$3.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.